NCT03684798 (MCIIAUD) is a NA clinical trial of MCII in Alcohol Use Disorder, sponsored by Susanne Rösner.

Who is sponsoring NCT03684798?

NCT03684798 is sponsored by Susanne Rösner.

What drugs are being tested in NCT03684798?

Interventions in NCT03684798: MCII, Treatment as usual.

What condition does NCT03684798 study?

NCT03684798 studies Alcohol Use Disorder.

Is NCT03684798 still recruiting?

NCT03684798 is currently completed. Last updated 5 February 2020.

Last reviewed 2020-02-05 · How we verify

NCT03684798: MCIIAUD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mental Contrasting With Implementation Intentions for Alcohol Use Disorders

Completed NA Last updated 5 February 2020

What this trial tests

NA trial testing MCII in Alcohol Use Disorder in 122 participants. Completed in 4 March 2019.

Timeline

14 August 2017

Primary endpoint
4 March 2019

4 March 2019

Quick facts

Lead sponsor	Susanne Rösner
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	122
Start date	14 August 2017
Primary completion	4 March 2019
Estimated completion	4 March 2019
Sites	1 location across Switzerland

Drugs / interventions tested

MCII
Treatment as usual

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →

Sponsor

Susanne Rösner

Who can join

18 and older, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality in order to increase goal commitment when expectations of success are high. The study aims to investigate the effects of a motivational training (Mental Contrasting with Implementation Interventions; MCII) as a therapeutic add-on to standard treatment in inpatients with Alcohol Use Disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03684798 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Susanne Rösner
Last refreshed: 5 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing